38 results about "Chenodeoxycholic acid" patented technology

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The invention provides a composition containing bile acid and bifidobacterium animalis subsp. Lactis for improving tear stains of dogs and cats. The composition is prepared from the bile acid and the bifidobacterium animalis subsp. Lactis ZYhyy-017, and the composition is prepared from the bile acid, the bifidobacterium animalis subsp. Lactis ZYhyy-017, the bifidobacterium animalis subsp. Lactis ZYhyy-017 and the bifidobacterium animalis subsp. Lactis ZYhyy-017. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.37292, and the preservation date is January 6, 2026. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The bile acid is chenodeoxycholic acid (CDCA). The composition regulates and controls a bile acid-porphyrin metabolic pathway in a targeted manner through the synergistic effect of bile acid and bifidobacterium animalis subsp. Lactis ZYhyy-017, porphyrin metabolism in pets is regulated from the source, intestinal and liver axis metabolism and liver functions are optimized, long-acting and safe improvement of tear stains of dogs and cats is achieved, and the composition has a wide application prospect. Meanwhile, the technical blank that bile acid and specific probiotics are synergistically applied to the field of tear stain improvement of dogs and cats is filled up, and the actual requirement for tear stain root improvement in pet feeding is met.

The invention discloses a synthesis method of N-goose deoxycholyl-L-aspartic acid and application of the N-goose deoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolism-related fatty liver diseases. According to the method provided by the invention, chenodeoxycholic acid and L-dimethyl aspartate hydrochloride are taken as raw materials, and a chenodeoxycholic acid-dimethyl aspartate intermediate is synthesized, so that a target compound-N-chenodeoxycholyl-L-aspartic acid with a brand new structure is efficiently prepared. The compound shows a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as fatty degeneration, inflammation and fibrosis of the liver. The invention provides a brand new solution for major clinical challenges of insufficient curative effect, large side effect, drug withdrawal rebound and the like of the current MAFLD treatment drug, and provides a candidate compound with a wide prospect for developing a novel efficient MAFLD treatment drug.

This invention provides a 7β-HSDH enzyme mutant, its encoding gene, and its applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

The invention provides an impurity removal method of a chenodeoxycholic acid crude product, which comprises the following steps: dissolving the chenodeoxycholic acid crude product and glucose in a solvent, adding alkali to control the pH value of the system to be 8-10, and adding thiourea to react so as to convert 22-ene-chenodeoxycholic acid impurities into chenodeoxycholic acid. According to the impurity removal method provided by the invention, the 22-ene-chenodeoxycholic acid impurity in chenodeoxycholic acid can be effectively removed without adopting a heavy metal catalyst and the like, and the method is convenient to operate, mild in condition, low in production risk and suitable for large-scale industrial production.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

The invention relates to the technical field of aquaculture feed, in particular to a feed additive for improving ovary color of scylla paramamosain and application of the feed additive. The feed additive is prepared from the following raw material components in parts by mass: 30-60 parts of Chinese wolfberry fruit powder, 10-30 parts of a marigold extract, 2-8 parts of chenodeoxycholic acid and 5-15 parts of vitamin E powder. The additive systematically solves the technical bottlenecks of low absorptivity and unstable deposition of natural pigments in crab bodies through the synergistic effect of all the components. When the feed additive is added into feed for fattening female scylla paramamosain, the ovary redness value can be remarkably increased, the color is rich and natural, and meanwhile, the growth of parent crabs and the development of gonad are promoted. The feed is completely prepared from natural raw materials, is safe, free of residues and controllable in cost, and provides an effective scheme for realizing high-valued and green cultivation of scylla paramamosain'red cream crab '.

The application discloses a synthesis method of N-chenodeoxycholyl-L-aspartic acid and application of the N-chenodeoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolic associated fatty liver disease. The method provided by the application uses chenodeoxycholic acid and L-aspartic acid dimethyl ester hydrochloride as raw materials, synthesizes a chenodeoxycholic acid-aspartic acid dimethyl ester intermediate, and efficiently prepares a target compound, N-chenodeoxycholyl-L-aspartic acid, which is a novel structure, the compound exhibits a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as liver steatosis, inflammation and fibrosis. The application provides a novel solution for major clinical challenges such as insufficient treatment effect, large side effect and rebound after drug withdrawal of current MAFLD treatment medicines, and provides a candidate compound with broad prospects for developing a new high-efficiency MAFLD treatment medicine.

This invention relates to the field of traditional Chinese medicine technology, specifically to a composition for clearing heat and detoxifying, protecting the liver and improving eyesight, its pharmaceutical preparation and application. The raw materials of the composition, by weight, include the following components: 10-30 parts ursodeoxycholic acid, 1-5 parts chenodeoxycholic acid, 5-15 parts Lycium barbarum polysaccharide, 5-18 parts betaine, 1-5 parts glycyrrhizic acid, 0.2-5 parts glycyrrhetinic acid, and 1-5 parts glycyrrhizin. This invention combines these components to achieve the effects of clearing heat and detoxifying, protecting the liver and improving eyesight. Pharmacological experiments have demonstrated that it has significant antipyretic effects, prevents and treats eye fatigue, and improves acute liver injury.

The invention discloses a silanization purification method for ursodesoxycholic acid prepared by a biological enzyme method, and belongs to the field of biological pharmacy. According to the method, the whole-cell reaction liquid is used as a purification object, insoluble macromolecular impurities are removed through preliminary impurity removal and high-concentration acetone-water dissolution, the target content of UDCA is 80% or above successfully, and the product is pure white; the method comprises the following steps: carrying out a reaction on a UDCA silanization derivative and-OH by using a silanization reagent, separating the UDCA silanization derivative from other silanization derivatives, and hydrolyzing the UDCA silanization derivative to realize purification of UDCA. The content of CDCA in the final product is effectively controlled to be 0.5% or below, the purity of the UDCA crude product is improved from 53% to 98.5% or above, and the requirements of UDCA bulk drugs are met. The method is simple in process and low in cost, the obtained product is high in purity, the chenodeoxycholic acid impurity content is low, and the chenodeoxycholic acid can be used as a raw material of a pharmaceutical preparation.

The present invention relates to the field of medicinal chemistry. Specifically disclosed is a use of oxime-based cholic acid (CA) analogs as allosteric agonists for TGR5. In the present invention, CA used as a raw material undergoes a series of reactions to obtain CA intermediates each having an oxime at either or both of positions 7 and 12, and a series of modifications are then carried out on positions 24 and the oximes of these intermediates to obtain CA analogs as represented by formula 1, formula 2, or formula 3. The present invention uses a GloSensor cAMP accumulation assay to test the functional activity and allosteric mechanism of all target compounds on TGR5. Pharmacological results have shown that all synthesized target compounds have relatively good agonistic activity on TGR5 and can positively allosterically regulate the functional activity of chenodeoxycholic acid (CDCA) or lithocholic acid (LCA), that is, the target compounds are all positive allosteric modulators or allosteric agonists for TGR5.

This invention provides a 7α-HSDH enzyme mutant and a 7β-HSDH enzyme mutant, their encoding genes, and their applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

The application discloses a preparation method of chenodeoxycholic acid. The method uses 22E-3alpha-acyloxy-7-ketone-cholest-5,22-diene-24-carboxylic acid methyl ester as raw material, and one-pot three-site hydrogenation reduction of an olefinic bond and a carbonyl group is simultaneously carried out under the reduction condition of a metal catalyst to obtain a 5beta-hydrogen-7alpha-hydroxyl intermediate with high selectivity, and then chenodeoxycholic acid is obtained through hydrolysis. The method for preparing chenodeoxycholic acid directly constructs two chiral centers (5beta and 7alpha) through one-step hydrogenation. The reaction has the characteristics of simplicity, high efficiency, safe operation, high stereoselectivity and convenient product purification, can effectively prepare chenodeoxycholic acid, and is suitable for industrialization. The application has wide application prospect.

The invention relates to the technical field of biology, and particularly discloses combined application of chenodeoxycholic acid and an anti-PD-1 inhibitor in cancer resistance. The research finds that the anti-tumor effect can be effectively improved through combined use of chenodeoxycholic acid and an anti-PD-1 inhibitor, and then the application of the combined use of the chenodeoxycholic acid compound and the anti-PD-1 inhibitor in preparation of drugs for treating cancers is provided, the chenodeoxycholic acid compound is chenodeoxycholic acid or pharmaceutically acceptable salt, prodrug and metabolite of chenodeoxycholic acid; in a unit preparation of the medicine, the mass ratio of the chenodeoxycholic acid compound to the anti-PD-1 inhibitor is (2.9-26): 1 on the basis of the mass of the chenodeoxycholic acid and the anti-PD-1 inhibitor. According to the method, the anti-tumor effect can be improved, the drug dosage is reduced, the toxic and side effects are reduced, the occurrence of drug resistance is reduced, and an effective new method is provided for tumor treatment.

The invention relates to the technical field of biological medicine chemical separation, and discloses a separation and purification process of high-purity ursodesoxycholic acid mother liquor, which comprises the following steps: adding alkaline amino acid into the mother liquor containing ursodesoxycholic acid, stirring and dissolving to obtain a water phase system; adding a neutral chiral hydrophobic deep-eutectic solvent formed by complexing L-menthol and long-chain fatty alcohol into the water-phase system, and carrying out mixed extraction; standing for layering, separating to remove an upper-layer oil phase, and collecting a lower-layer water phase; finally, acid is added into the water phase to adjust the pH value, and an ursodesoxycholic acid product is obtained through ultrasonic-assisted crystallization, cleaning and drying. According to the method disclosed by the invention, efficient separation of a target product from chenodeoxycholic acid and lithocholic acid is realized by utilizing the specific hydrophilic anchoring effect of the basic amino acid on ursodeoxycholic acid and cooperating with the chiral hydrophobic recognition effect of the eutectic solvent on impurities. The process is green and environment-friendly, the solvent can be recycled, and the obtained product is high in purity and suitable for industrial application.

This invention discloses the application of *Gastrococcus xanthophylloides* in regulating intestinal bile acid metabolism disorders, including *Gastrococcus xanthophylloides* (… Ruminococcus flavefaciens The application of this invention in the preparation of compositions for regulating intestinal bile acid metabolism disorders, wherein the compositions promote the conversion of primary bile acids to secondary bile acids, wherein the primary bile acids include cholic acid and chenodeoxycholic acid, and the secondary bile acids include deoxycholic acid and lithocholic acid; wherein the intestinal bile acid metabolism disorders include metabolic disorders caused by antibiotics, wherein the antibiotics include one or more of moxifloxacin and metronidazole; wherein the compositions can be health products, pharmaceuticals, or feed; and wherein the active ingredient of the compositions includes xanthospirococcus flavus.

The invention discloses a preparation method of high-purity ursodesoxycholic acid, and belongs to the technical field of biological medicines. The method provided by the invention specifically comprises the following steps: carrying out a catalytic oxidation reaction on chenodeoxycholic acid by using 7 alpha-hydroxysteroid dehydrogenase to generate a 7-ketolithocholic acid intermediate, and then carrying out a catalytic reduction reaction on 7 beta-hydroxysteroid dehydrogenase to generate a crude ursodeoxycholic acid product. Further, the crude ursodesoxycholic acid reacts with a triethylamine reagent to generate ursodesoxycholic acid triethylamine salt, and a part of cell impurities are removed; dropwise adding an acid reagent to hydrolyze ursodesoxycholic acid triethylamine salt; and finally, recrystallizing and refining by using ethyl acetate and ethanol to obtain high-purity ursodesoxycholic acid. The method is simple in process and low in cost, the obtained product is high in purity, few organic reagents are used, environmental pollution is little, and industrial production can be achieved.

The application provides a dog and cat tear mark improvement composition containing bile acid and Bifidobacterium animalis subsp. lactis, the composition containing bile acid and Bifidobacterium animalis subsp. lactis ZYhyy-017; the Bifidobacterium animalis subsp. lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No. 37292, and the preservation date is January 6, 2026; the bile acid is chenodeoxycholic acid (CDCA). The composition targets the regulation of the bile acid-porphyrin metabolic pathway through the synergistic effect of bile acid and Bifidobacterium animalis subsp. lactis ZYhyy-017, adjusts the porphyrin metabolism in pets from the root, optimizes the intestinal-liver axis metabolism and liver function, realizes the long-term and safe improvement of dog and cat tear marks, fills the technical blank of the application of bile acid and specific probiotics in the field of dog and cat tear mark improvement, and meets the actual needs of pet feeding in tear mark root improvement.

The invention provides application of taurochenodeoxycholic acid and / or chenodeoxycholic acid and polyinosinic acid combined medicine in preparation of medicine for preventing and / or treating melanoma, and belongs to the field of biological medicine. It is found for the first time that taurochenodeoxycholic acid and / or chenodeoxycholic acid can influence the tumor immune microenvironment by regulating and controlling the antigen presentation function of cDC1, and the treatment effect of polyinosinic-cytidylic acid is improved. The melanoma model experiment directly shows that the combination of chenodeoxycholic acid and polyinosinic-cytidylic acid can better inhibit tumor growth, can effectively promote CD8 + T cell infiltration in tumors, has more cDC1 infiltration in tumor tissues, shows a stronger inhibition effect on tumors, and can be used for preparing drugs for treating tumors. The pharmaceutical composition plays a synergistic role in treatment of melanoma, and provides a new choice for clinical treatment of melanoma.

The utility model relates to the technical field of chenodeoxycholic acid crystal production and processing, and discloses a chenodeoxycholic acid concentration and crystallization tank which comprises a shell, the upper surface of the shell is slidably connected with a top cover, the upper surface of the top cover is provided with a filter assembly, the lower surface of the shell is fixedly connected with a temporary storage cover, and the temporary storage cover is provided with a storage cavity. An inner shell is fixedly connected to the interior of the temporary storage cover, a heating wire is fixedly connected to the outer wall of the inner shell, a first support is fixedly connected to the upper surface of the top cover, and a stirring assembly is arranged on the inner wall of the first support; the stirring assembly comprises a motor, the outer wall of the motor is fixedly connected to the inner wall of the first support, and the output end of the motor is fixedly connected with a rotating shaft. According to the chenodeoxycholic acid crystal stirring device, through the shape design of the square stirring blades, crystals attached to the inner wall of the inner shell can be scraped off, the situation that the finally obtained chenodeoxycholic acid crystals are reduced due to the fact that the crystals are attached to the inner wall of the inner shell is avoided, and the production efficiency of the chenodeoxycholic acid crystals is improved.

A method for preparing a squalamine key intermediate of formula (I), wherein R is as defined in the description. In the method, 5α-chenodeoxycholic acid is used as a raw material, and is reacted with a Weinreb reagent to obtain a Weinreb amide; then, the Weinreb amide is sequentially subjected to an oxidation reaction, a ketalization reaction with ethylene glycol, and a nucleophilic reaction with an organometallic reagent, and is finally subjected to a reductase-catalyzed asymmetric carbonyl reduction reaction to obtain the compound of formula I. The method has the advantages of simple steps, high overall yield, high product purity, etc., and is suitable for industrial production.

Provided are: an FPR1 inhibitor that can be used in a therapeutic agent based on cell death pathology specific to SJS / TEN, and that that can ameliorate the death rate of SJS / TEN; a drug; and a severe drug eruption therapeutic agent. Moreover, provided is an FPR1 inhibitor screening method for seeking these therapeutic agents. The FPR1 inhibitor, the drug, and the severe drug eruption therapeutic agent contain chenodeoxycholic acid or sulfinpyrazone as an active ingredient, and are used for treating severe drug eruption. The FPR1 inhibitor screening method is for seeking these therapeutic agents.

This invention belongs to the field of veterinary pharmacy and relates to the application of chenodeoxycholic acid (CDCA) in the preparation of drugs for treating canine acute pancreatitis. This invention is the first to propose the application of CDCA in the preparation of drugs for treating canine acute pancreatitis, clarifying that it achieves therapeutic effects by reducing pancreatic CT values, alleviating pancreatic edema and necrosis, and improving pancreatic tissue pathological damage, providing a novel strategy and drug option for targeted treatment of canine acute pancreatitis.

This invention belongs to the field of biomedical technology, specifically relating to the application of reagents for detecting the expression levels of compounds in samples in the preparation of diagnostic products for acute altitude sickness. The compounds used in this invention are derived from one or more of CAR 16:0, CAR 18:0, CAR 18:1, CAR 18:2, LPC 18:0, LPC 18:1, LPC 16:1, and chenodeoxycholic acid. This invention provides compounds capable of determining whether a subject develops acute altitude sickness in the early stages of altitude exposure, and therefore proposes the application of reagents for detecting the expression levels of these compounds in samples in the preparation of diagnostic products for acute altitude sickness.

This invention relates to the field of artificial bear bile powder preparation technology, specifically to a novel 7α-hydroxysteroid dehydrogenase gene R-α-1 and its application in the production and conversion of bear bile powder. This method isolates a novel gene catalyzing asymmetric carbonyl reduction reactions from the feces of Sichuan brown bears. This gene encodes a 7α-hydroxysteroid dehydrogenase, which catalyzes the formation of the intermediate tauroursodeoxycholic acid from tauroursodeoxycholic acid, which is further catalyzed by a 7β-hydroxysteroid dehydrogenase to produce tauroursodeoxycholic acid, the main component of bear bile powder. The nucleotide sequence of this gene is shown in SEQ ID NO.1, and its encoded amino acid sequence is shown in SEQ ID NO.2. This technical solution can solve the technical problem that existing types of 7α-hydroxysteroid dehydrogenases cannot meet the needs of large-scale production due to unsatisfactory enzyme activity and thermostability, and has ideal prospects for widespread application.

The invention provides application of taurochenodeoxycholic acid and / or chenodeoxycholic acid and PD-1 antibody combined medicine in preparation of medicine for preventing and / or treating melanoma, and belongs to the field of biological medicine. It is found for the first time that taurochenodeoxycholic acid and / or chenodeoxycholic acid can influence the tumor immune microenvironment and improve the treatment effect of the PD-1 antibody by regulating and controlling the function of cDC1. The melanoma model experiment directly shows that the combination of chenodeoxycholic acid and the PD-1 antibody can better inhibit tumor growth, and can effectively promote CD8 + T cell infiltration in tumor, so that more cDC1 infiltration exists in tumor tissue, the stronger inhibition effect on tumor is displayed, and the application of chenodeoxycholic acid and PD-1 antibody in tumor treatment is realized. The pharmaceutical composition plays a synergistic role in treatment of melanoma, and provides a new choice for clinical treatment of melanoma.

The invention discloses a blood metabolism marker for evaluating the effect of interfering and improving lipid metabolism by intestinal strains and application of the blood metabolism marker, and belongs to the technical field of biomarkers. The blood metabolism marker comprises 13 kinds of common difference metabolites and 6 kinds of target cholic acid metabolites, the 13 kinds of common difference metabolites are cholest-4-ene-3-ketone, 1-phenyl-1H-pyrrole-2, 5-diketone and the like, and the 6 kinds of target cholic acid metabolites are cholic acid, 7-ketodeoxycholic acid, chenodeoxycholic acid and the like. The blood metabolism marker can accurately reflect the improvement effect of intestinal strain intervention on lipid metabolism, can be applied to preparation of a detection reagent or kit for evaluating the intervention effect of the intestinal strain, and can also be used for evaluating the improvement effect of lipid metabolism and monitoring the intervention effect of the intestinal strain. A detection index with high specificity and high sensitivity is provided for evaluating the effect of interfering the lipid metabolism by the intestinal strain, and the method has an important practical application value.

The invention discloses application of chenodeoxycholic acid in preparation of drugs for promoting healing of diabetic wounds, and belongs to the technical field of medicines. The invention proves that CDCA can reverse fibroblast dysfunction induced by high glucose in a dose-dependent manner, remarkably improve cell proliferation and migration ability and repair expression of related genes (PCNA, alpha-SMA and Vimentin), and shows that CDCA has the characteristic of improving wound surface microenvironment by regulating and controlling multi-cell functions and has important clinical transformation value.

The utility model relates to the technical field of pharmaceutical engineering, disclose goose deoxycholic acid crystallization integrated device, including crystallization kettle, the upper surface of crystallization kettle is connected with the crystallization kettle cover plate slidingly, the inner wall of crystallization kettle cover plate is fixedly connected with telescopic water pipe, the upper surface of crystallization kettle cover plate is fixedly connected with flange shaft sleeve, the upper surface of flange shaft sleeve is fixedly connected with connecting plate, the upper surface of connecting plate is fixedly connected with motor, the output of motor is fixedly connected with bearing, the lower surface of bearing is fixedly connected with shaft body, the output of motor is fixedly connected with paddle, the inside of crystallization kettle is provided with cleaning mechanism, in the utility model, through telescopic pipe spherical shower nozzle, telescopic rod is used as water inlet valve connection shower nozzle part, can directly to the bottom of device work, the spherical shower nozzle can be without dead angle spray in the crystallization kettle inner wall cleaning fluid, and the problem of not easy to clean is improved.